SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024 after the market closes. Company management will host a conference call at 4:30 p.m. ET that day to discuss financial results and provide a business update.
Conference Call & Webcast
Thursday, August 8th @ 4:30 PM ET
| Domestic: | 1-800-267-6316 |
| International: | 1-203-518-9783 |
| Conference ID: | CRNXQ2 |
Participants can use the dial-in numbers above OR access the call via live webcast on the Events section of the Crinetics website. To ensure a timely connection, it is recommended that participants dial-in or register at least 15 minutes prior to scheduled start of the call.
The webcast will be archived on the Investor Relations sections of www.crinetics.com.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, first-in-class, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant (CRN04894), an investigational, first-in-class, oral ACTH antagonist, that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. All of the Company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease, thyroid eye disease, diabetes and obesity.
Contact:
Gayathri Diwakar
Head of Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
(858) 345-6075
| Last Trade: | US$50.39 |
| Daily Change: | -0.59 -1.16 |
| Daily Volume: | 508,426 |
| Market Cap: | US$4.030B |
August 08, 2024 May 09, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MORE
